Anupam Rasayan India Limited has informed the Exchange regarding a press release dated May 23, 2026, titled "Press Release- Bliss GVS Pharma Limited Acquisition ".
ANURAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anupam Rasayan India Limited has entered into a definitive agreement to acquire a 43.3%-48.2% equity stake in Bliss GVS Pharma Limited, a listed pharmaceutical formulations company. The company is also making an Open Offer to the public shareholders of Bliss GVS Pharma. The total purchase consideration of Rs 300 Crores is being financed via Term Loan, with the balance through a non-controlling non-voting equity instrument. Bliss GVS Pharma is engaged in manufacturing and export of pharmaceutical dosage forms including suppositories, tablets, capsules, and injectables, with strong presence in Africa, Asia, and Latin America markets. The acquisition will help Anupam expand from specialty chemicals into finished pharmaceutical formulations.
This acquisition marks Anupam Rasayan's strategic entry into pharmaceutical formulations, creating an integrated platform spanning KSMs to finished dosage forms. The Open Offer component is mandatory under SEBI regulations, potentially affecting Bliss GVS Pharma's minority shareholders. For Anupam shareholders, this deal diversifies revenue streams and strengthens regulated market presence.